BrainSee
Prognosis of Mild Cognitive Impairment (MCI) due to Alzheimer's Disease
Key Facts
About Darmiyan
Darmiyan has developed a novel AI-powered diagnostic platform, BrainSee, which received De Novo FDA approval for predicting the 5-year prognosis of patients with mild cognitive impairment (MCI). The technology analyzes routine MRI scans at a voxel level to create a 'virtual microscope' of the brain, aiming to detect neurodegenerative changes years before clinical symptoms manifest. Backed by validation studies showing ~90% accuracy and investment from pharmaceutical giant Eisai, Darmiyan is positioned to address a critical gap in early Alzheimer's disease detection and intervention monitoring. The company operates as a private, commercial-stage diagnostics firm with a clear focus on revolutionizing the brain health paradigm.
View full company profile